Skip to main content

Advertisement

SpringerLink
Log in

Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

To provide more precise treatment options for pancreatic adenocarcinoma (PAAD) patients and improve their prognosis,we established a novel anoikis-related long non-coding RNA signature (ARLSig) to predict the prognosis and immune response for PAAD patients.

Methods

We downloaded information on PAAD from The Cancer Genome Atlas (TCGA) database, and screened long non-coding RNA (lncRNA) linked with anoikis, and prognostic signatures with these lncRNAs. After that, ARLSig was verified using receiver operating characteristic (ROC) and C-index curves. To further investigate the role of ARLSig, we also performed enrichment analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). Additionally, using immunological correlation analysis and single-sample genetic enrichment analysis, we investigated the effectiveness of PAAD immunotherapy.

Results

We screened 7 lncRNAs to construct a novel ARLSig and utilized it to predict the efficacy of immunotherapy and the prognosis of PAAD patients.

Conclusion

ARLSig can identify patients who will benefit from immunotherapy and improve the prediction of PAAD patient prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data availability

The analyzed data sets generated during the study are available from the corresponding author upon reasonable request.

References

  • Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y et al (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551:512–516 (Epub 20171108)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bauer C, Kühnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M (2016) Prevailing over T cell exhaustion: new developments in the immunotherapy of pancreatic cancer. Cancer Lett 381:259–268 (Epub 20160308)

    Article  CAS  PubMed  Google Scholar 

  • Bu F, Yin S, Guan R, Xiao Y, Zeng S, Zhao Y (2022) Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma: a review. Medicine (Baltimore) 101:e31747

    Article  CAS  PubMed  Google Scholar 

  • Buchheit CL, Weigel KJ, Schafer ZT (2014) Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 14:632–641 (Epub 20140807)

    Article  CAS  PubMed  Google Scholar 

  • Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30:44–56

    Article  CAS  PubMed  Google Scholar 

  • Chen H, Xie J, Jin P (2020) Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma. Am J Transl Res 12:7096–7113 (Epub 20201115)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chen X, Kang R, Kroemer G, Tang D (2021) Targeting ferroptosis in pancreatic cancer: a double-edged sword. Trends Cancer 7:891–901 (Epub 20210520)

    Article  CAS  PubMed  Google Scholar 

  • Chi H, Peng G, Wang R, Yang F, Xie X, Zhang J, Xu K, Gu T, Yang X, Tian G (2022) Cuprotosis programmed-cell-death-related lncRNA signature predicts prognosis and immune landscape in PAAD patients. Cells 11:3436 (Epub 20221031)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chiarugi P, Giannoni E (2008) Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 76:1352–1364 (Epub 20080725)

    Article  CAS  PubMed  Google Scholar 

  • Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15:7–21 (Epub 20131203)

    Article  CAS  PubMed  Google Scholar 

  • Flowers BM, Xu H, Mulligan AS, Hanson KJ, Seoane JA, Vogel H, Curtis C, Wood LD, Attardi LD (2021) Cell of origin influences pancreatic cancer subtype. Cancer Discov 11:660–677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fofaria NM, Srivastava SK (2015) STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 36:142–150 (Epub 20141119)

    Article  CAS  PubMed  Google Scholar 

  • Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626

    Article  CAS  PubMed  Google Scholar 

  • Fusco MJ, West HJ, Walko CM (2021) Tumor mutation burden and cancer treatment. JAMA Oncol 7:316

    Article  PubMed  Google Scholar 

  • Gao X, Zhang W, Jia Y, Xu H, Zhu Y, Pei X (2022) Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking. Sci Rep 12:16247 (Epub 20220928)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • [Guidelines for the diagnosis and treatment of pancreatic cancer in China(2021)]. 2021. Zhonghua Wai Ke Za Zhi;59:561–577.

  • Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R (2021) The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39:154–173 (Epub 20201029)

    Article  CAS  PubMed  Google Scholar 

  • Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klebanov N, Artomov M, Goggins WB, Daly E, Daly MJ, Tsao H (2019) Burden of unique and low prevalence somatic mutations correlates with cancer survival. Sci Rep 9:4848 (Epub 20190319)

    Article  PubMed  PubMed Central  Google Scholar 

  • Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670–691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li L, He Z, Zhu C, Chen S, Yang Z, Xu J, Bi N, Yu C, Sun C (2020a) MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer. J Cancer 11:6277–6285 (Epub 20200828)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48:W509-w514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liang L, Xia W, Yao L, Wu Q, Hua L, Cheng G, Wang Z, Zhao R (2021) Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma. Int Immunopharmacol 101:108267 (Epub 20211102)

    Article  CAS  PubMed  Google Scholar 

  • Liang X, Zha L, Yu G, Guo X, Qin C, Cheng A, Wang Z (2022) Construction and comprehensive prognostic analysis of a novel immune-related lncRNA signature and immune landscape in gastric cancer. Int J Genom 2022:4105280 (Epub 20220117)

    Google Scholar 

  • Liu JL, Zhang WQ, Zhao M, Huang MY (2019) Upregulation of long noncoding RNA XIST is associated with poor prognosis in human cancers. J Cell Physiol 234:6594–6600 (Epub 20181020)

    Article  CAS  PubMed  Google Scholar 

  • Liu D, Zhao J, Wang H, Li H, Li Y, Qin W (2020a) Long intergenic non-protein coding RNA 519 promotes the biological activities of tongue squamous cell carcinoma by sponging microRNA-876-3p and consequently upregulating MACC1. Onco Targets Ther 13:11975–11990 (Epub 20201120)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Z, Wang Z, Wang X, Lu M, Chen G (2020b) Long noncoding RNA HOTTIP serves as an independent predictive biomarker for the prognosis of patients with clear cell renal cell carcinoma. Int J Genom 2020:4301634 (Epub 20200514)

    Google Scholar 

  • Liu X, Zhang X, Du S (2022) Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2. Cell Cycle 21:368–378 (Epub 20220105)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS (2018) Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24:4846–4861

    Article  PubMed  PubMed Central  Google Scholar 

  • Meng Z, Lv Q, Lu J, Yao H, Lv X, Jiang F, Lu A, Zhang G (2016) Prodrug strategies for paclitaxel. Int J Mol Sci 17:796 (Epub 20160523)

    Article  PubMed  PubMed Central  Google Scholar 

  • Paoli P, Giannoni E, Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833:3481–3498 (Epub 20130702)

    Article  CAS  PubMed  Google Scholar 

  • Shang Y (2018) LncRNA THOR acts as a retinoblastoma promoter through enhancing the combination of c-myc mRNA and IGF2BP1 protein. Biomed Pharmacother 106:1243–1249 (Epub 20180720)

    Article  CAS  PubMed  Google Scholar 

  • Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33 (Epub 20220112)

    Article  PubMed  Google Scholar 

  • Song JP, Liu XZ, Chen Q, Liu YF (2022) High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma. World J Clin Cases 10:790–801

    Article  PubMed  PubMed Central  Google Scholar 

  • Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C (2022) Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol 13:939523 (Epub 20220825)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249 (Epub 20210204)

    Article  PubMed  Google Scholar 

  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703 (Epub 20131016)

    Article  Google Scholar 

  • Wang W, Ye Y, Zhang X, Ye X, Liu C, Bao L (2022) Construction of a necroptosis-associated long non-coding RNA signature to predict prognosis and immune response in hepatocellular carcinoma. Front Mol Biosci 9:937979 (Epub 20220713)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang W, Ye Y, Zhang X, Sun W, Bao L (2023) An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. Heliyon 9:e13989 (Epub 20230223)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327

    Article  CAS  PubMed  Google Scholar 

  • Wu J, Sun S, Liao W, Chen E, Wang X, Song Y, Duan F, Deng W, Li S (2021) LINC00460 promotes pancreatic cancer progression by sponging miR-491–5p. J Gene Med 23:e3333 (Epub 20210510)

    Article  CAS  PubMed  Google Scholar 

  • Yang L, Xu F (2023) A novel anoikis-related risk model predicts prognosis in patients with colorectal cancer and responses to different immunotherapy strategies. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-023-04945-2. (Epub 20230615)

    Article  PubMed  PubMed Central  Google Scholar 

  • Ye P, Lv X, Aizemaiti R, Cheng J, Xia P, Di M (2020) H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515–5p/YAP1 axis. Cell Prolif 53:e12797 (Epub 20200416)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ye Y, Zhao Q, Wu Y, Wang G, Huang Y, Sun W, Zhang M (2022) Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma. Front Genet 13:989719 (Epub 20220923)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu B, Gu D, Zhang X, Liu B, Xie J (2022) Regulation of pancreatic cancer metastasis through the Gli2-YAP1 axis via regulation of anoikis. Genes Dis 9:1427–1430 (Epub 20220524)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang X, Zhao X, Chang L, Liu F, Li C, Ge P (2022) LncRNA FOXD3-AS1 promotes breast cancer progression by mediating ARF6. Breast Cancer 29:908–920 (Epub 20220609)

    Article  PubMed  Google Scholar 

  • Zhao K, Li X, Shi Y, Lu Y, Qiu P, Deng Z, Yao W, Wang J (2022) A comprehensive analysis of pyroptosis-related lncRNAs signature associated with prognosis and tumor immune microenvironment of pancreatic adenocarcinoma. Front Genet 13:899496 (Epub 20220706)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng Y, Yue X, Fang C, Jia Z, Chen Y, Xie H, Zhao J, Yang Z, Li L, Chen Z et al (2022) A novel defined endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune therapy in glioma. Front Oncol 12:930923 (Epub 20220630)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We appreciate all the participants who supported our research. We acknowledge TCGA and GEO databases for providing their platforms and contributors for uploading their meaningful data sets.

Funding

The authors have not disclosed any funding.

Author information

Author notes

  1. Yue Jiang, Yingquan Ye and Yi Huang have contributed equally to this work.

Authors and Affiliations

  1. Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affifiliated Hospital of Anhui Medical University, Hefei, 230022, China

    Yue Jiang, Yingquan Ye, Yi Huang, Yue Wu, Gaoxiang Wang, Zhongxuan Gui, Mengmeng Zhang & Mei Zhang

  2. The Traditional and Western Medicine (TCM)- Integrated Cancer Center of Anhui Medical University, Hefei, 230022, China

    Yue Jiang, Yingquan Ye, Yi Huang, Yue Wu, Gaoxiang Wang, Zhongxuan Gui, Mengmeng Zhang & Mei Zhang

  3. Anhui University of Traditional Chinese Medicine, Hefei, 230022, China

    Mei Zhang

Authors
  1. Yue Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yingquan Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yue Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gaoxiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhongxuan Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mengmeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yue Jiang and Yingquan Ye designed the study. Yi Huang and Yue Wu collected the literature. Gaoxiang Wang and Zhongxuan Gui analyzed the data. Mengmeng Zhang and Yue Jiang drafted the manuscript. Mei Zhang modified the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding author

Correspondence to Mei Zhang.

Ethics declarations

Conflicts of interest

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 KB)

Supplementary file2 (XLS 3143 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Y., Ye, Y., Huang, Y. et al. Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response. J Cancer Res Clin Oncol 149, 15069–15083 (2023). https://doi.org/10.1007/s00432-023-05285-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-05285-x

Keywords

Search

Navigation